Literature DB >> 21321297

Correcting for discretionary treatment crossover in an analysis of survival in the Breast International Group BIG 1-98 trial by using the inverse probability of censoring weighted method.

Dianne M Finkelstein, David A Schoenfeld.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21321297     DOI： 10.1200/JCO.2010.33.9374

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

1.  Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

Authors:  Meredith M Regan; Patrick Neven; Anita Giobbie-Hurder; Aron Goldhirsch; Bent Ejlertsen; Louis Mauriac; John F Forbes; Ian Smith; István Láng; Andrew Wardley; Manuela Rabaglio; Karen N Price; Richard D Gelber; Alan S Coates; Beat Thürlimann
Journal:  Lancet Oncol       Date:  2011-10-20       Impact factor: 41.316

2.  A Multi-state Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression.

Authors:  Fang Xia; Stephen L George; Xiaofei Wang
Journal:  Stat Biopharm Res       Date:  2016-03-22       Impact factor: 1.452

3.  Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.

Authors:  Huan Jin; Dongsheng Tu; Naiqing Zhao; Lois E Shepherd; Paul E Goss
Journal:  J Clin Oncol       Date:  2011-10-31       Impact factor: 44.544

4.  Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.

Authors:  Otto Metzger Filho; Anita Giobbie-Hurder; Elizabeth Mallon; Barry Gusterson; Giuseppe Viale; Eric P Winer; Beat Thürlimann; Richard D Gelber; Marco Colleoni; Bent Ejlertsen; Marc Debled; Karen N Price; Meredith M Regan; Alan S Coates; Aron Goldhirsch
Journal:  J Clin Oncol       Date:  2015-07-27       Impact factor: 44.544

5.  Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma.

Authors:  T E Delea; A Khuu; D Y C Heng; T Haas; D Soulières
Journal:  Br J Cancer       Date:  2012-08-30       Impact factor: 7.640

Review 6.  Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.

Authors:  Meredith M Regan; Karen N Price; Anita Giobbie-Hurder; Beat Thürlimann; Richard D Gelber
Journal:  Breast Cancer Res       Date:  2011-05-26       Impact factor: 6.466

7.  Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy.

Authors:  Nicholas R Latimer; Helen Bell; Keith R Abrams; Mayur M Amonkar; Michelle Casey
Journal:  Cancer Med       Date:  2016-01-27       Impact factor: 4.452
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.